#Pioneering Advances in Ophthalmologic Care Clearside Biomedicals Suprachoroidal Platform at ARVO 2025

#Pioneering Advances in Ophthalmologic Care Clearside Biomedicals Suprachoroidal Platform at ARVO 2025

In the realm of ophthalmology, the continual quest for innovative treatments to address macular diseases has garnered significant attention, and Clearside Biomedical Inc. stands at the forefront of this endeavour. At the prestigious Association for Research in Vision and Ophthalmology (ARVO) 2025 meeting, emerging evidence was showcased through six compelling presentations that elucidated the efficacy of Clearside's suprachoroidal platform. This…

Isarna Therapeutics Presents Positive Phase 2 BETTER Trial Final Results

Isarna Therapeutics presented final positive results from its phase 2 BETTER trial at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting on May 6. Isarna’s Chief Medical Officer, Prof. Marion R. Munk, shared data on ISTH0036, a selective TGF-β2-blocking antisense oligonucleotide, in patients with wet age-related macular degeneration (AMD) and diabetic macular edema (DME). The study evaluated the potential of ISTH0036 …

Isarna Therapeutics presents positive phase 2 trial final results

Isarna Therapeutics presented final positive results from its Phase II BETTER trial at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting on 6th May.